Eric Stefanich - Senior Director & Distinguished Scientist, Preclinical and Translational PKPD (PTPK), Development Sciences

Eric Stefanich

Senior Director & Distinguished Scientist, Preclinical and Translational PKPD (PTPK), Development Sciences

"The path to longevity at Genentech involves having a strong mentor/role model, trusted network of colleagues, and exciting opportunities."
29
Years at Genentech
37
Publications at Genentech

I am a Senior Scientist and Group Leader in the PTPK group within Development Sciences. I am accountable for the pharmacology strategy from early stage research through first in human clinical trials for large molecule therapeutics in the areas of Immunology, Metabolic disease, Infectious disease, and Neurology.

Overall I have been at Genentech for over 21 years and have extensive drug development experience including writing regulatory documents as well as interactions with Health Authorities in US, Canada and Europe. I have also been team leader for the Pharmacology sub-team supporting several projects.

Featured Publication

A Humanized Monoclonal Antibody Targeting the Beta7 Integrin Selectively Blocks Intestinal Homing of T Lymphocytes.

Br J Pharmacol. 2011 Apr; 162(8): 1855–1870.

Stefanich EG, Danilenko DM, Wang H, O0Byrne S, Erickson R, Gelzleichter T, Hiraragi H, Chiu H, Ivelja S, Jeet S, Gadkari S, Hwang O, Fuh F, Looney C, Howell K, Albert V, Balazs M, Refino C, Fong S, Iyer S, Williams M.

Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study.

Clinical Pharmacology & Therapeutics, 2011; 89 (2):283-290.

Zheng Y, Scheerens H, Davis JC Jr, Deng R, Fischer SK, Woods C, Fielder PJ, Stefanich EG.